Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Geoffrey Glass Buys 16% More Shares

Potential Avadel Pharmaceuticals plc (NASDAQ:AVDL) shareholders may wish to note that the Independent Non-Executive Chairman of the Board, Geoffrey Glass, recently bought US$200k worth of stock, paying US$9.84 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 16%.

Check out our latest analysis for Avadel Pharmaceuticals

Avadel Pharmaceuticals Insider Transactions Over The Last Year

Notably, that recent purchase by Geoffrey Glass is the biggest insider purchase of Avadel Pharmaceuticals shares that we've seen in the last year. That implies that an insider found the current price of US$10.32 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the Avadel Pharmaceuticals insiders decided to buy shares at close to current prices.

While Avadel Pharmaceuticals insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Avadel Pharmaceuticals is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Avadel Pharmaceuticals

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.8% of Avadel Pharmaceuticals shares, worth about US$7.4m, according to our data. We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About Avadel Pharmaceuticals Insiders?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Avadel Pharmaceuticals insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we found 2 warning signs for Avadel Pharmaceuticals that deserve your attention before buying any shares.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.